Drug intelligence / Profile preview

BM-650

Development stage: Unknown
Lead developer: Biomissile Pharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BM-650 is a bispecific antibody drug candidate developed by Suzhou Biomissile Pharmaceuticals. It is currently in the discovery phase and is being investigated for the treatment of neoplasms (cancers). As a bispecific antibody, it is designed to simultaneously bind two different targets or antigens, which can enhance its therapeutic efficacy in oncology. However, specific details about its molecular targets, mechanism of action, or additional indications have not been disclosed publicly as of March 2025[1].

Beyond the preview

Go deeper on BM-650.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM-650.

Explore the full profile